EGFR and glioblastoma: EGFR is one of the main driver molecules in GBM and has been targeted by CAR-T cells, vaccines (rindopepimut), small inhibitors, mAbs (cetuximab) and antibody–drug conjugates (Depatux-M, ABBV–221) in phase I, II or III trials.